SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Singh, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Singh, N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Rosiglitazone and Heart Failure: Long-Term Vigilance

Nalini Singh, MD

Department of Endocrinology and Metabolism, Veterans Affairs Puget Sound Healthcare System, and University of Washington School of Medicine, Seattle, Washington; VA Puget Sound Healthcare System, Medicine-I1, 1660 South Columbian Way, Seattle, WA 98108; Nalini.Singh2{at}med.va.gov

Thiazolidinediones have become a powerful tool for lowering insulin resistance. In many short-term clinical studies, many patients taking thiazolidinediones experience significant improvement in glycemic control and lipid profiles without any adverse effects. Health care providers should be aware that, in long-term follow-up, peripheral edema and congestive heart failure may occur in patients with multiple comorbidities more than 26 weeks after starting thiazolidinediones. This article reports two patients who developed congestive heart failure 6 to 12 months after starting rosiglitazone, in combination with insulin. The patients' glycemic control improved over the first 3 to 6 months of therapy. When edema and congestive heart failure occurred later, they recovered only after medical therapy (diuretics, afterload reduction) was titrated and the rosiglitazone was withdrawn.

Key Words: rosiglitazone • thiazolidinedione • heart failure • edema

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 9, No. 1, 21-25 (2004)
DOI: 10.1177/107424840400900i104
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
H. J. Dargie, P. R. Hildebrandt, G. A.J. Riegger, J. J.V. McMurray, S. O. McMorn, J. N. Roberts, A. Zambanini, and J. P.H. Wilding
A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure
J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1696 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
N. Cekmen, M. Cesur, R. Cetinbas, P. Bedel, and O. Erdemli
Acute Pulmonary Edema Due to Rosiglitazone Use in a Patient With Diabetes Mellitus
J Intensive Care Med, January 1, 2006; 21(1): 47 - 50.
[Abstract] [PDF]


Advertisement